Your session is about to expire
← Back to Search
Chemotherapy for Triple Negative Breast Cancer
Study Summary
This trial is testing a new combination chemotherapy treatment for breast cancer patients with no estrogen receptors, progesterone receptors, or large amounts of human epidermal growth factor receptor 2 (HER2)/neu protein (triple negative).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any non-healing wounds or skin issues.I have a heart condition.I have stage II-III breast cancer that is ER, PgR, and HER2 negative.My cancer has spread to other parts of my body.I have been diagnosed with inflammatory breast cancer.I am eligible for surgery to treat my breast cancer.I have waited 4-6 weeks after surgery before starting liposomal doxorubicin.I had another type of cancer but it was treated over 5 years ago and hasn't come back.I am not pregnant or breastfeeding.I have a lung condition that makes it hard for me to breathe.I can do all or most of my daily activities without help.My life expectancy is at least one year, not counting my breast cancer.Your blood test results are normal.I have a moderate to severe nervous system disorder.I have had an organ transplant or need medicine to suppress my immune system.You have a condition that makes you prone to bleeding or blood clotting.I have symptoms of poor blood flow in my limbs.My cancer's size was checked by a doctor within the last 30 days.I have been treated with specific medications for cancer before.I have serious blood vessel problems.You have had bad reactions to certain medications in the past.I have hepatitis B or C with abnormal liver tests.I cannot take corticosteroids due to my health condition.My heart functions normally according to tests.I can provide tumor samples from my biopsy and breast surgery.I am not pregnant, confirmed by a recent test.
- Group 1: Treatment (doxil, carboplatin, surgery, paclitaxel)
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How is the combination of doxil, carboplatin, surgery and paclitaxel typically used to aid patients?
"Doxil, carboplatin, surgery and paclitaxel are frequently used to manage lymphoma and non-Hodgkin's diseases. These treatments can also be applied in the treatment of conditions like corticotropin, Kaposi's sarcoma AIDS related, and locally advanced non-small cell lung cancer."
What are the potential risks associated with utilizing doxil, carboplatin, surgery and paclitaxel for treatment?
"Our team at Power bestows a safety score of 2 upon this particular treatment (doxil, carboplatin, surgery, paclitaxel) due to limited efficacy data and extant evidence attesting to its security."
How many participants are benefitting from the current research trial?
"This clinical trial is currently not enrolling, having been last updated on March 28th 2023. Those searching for other studies may find 2386 trials actively recruiting patients with breast cancer and 1380 involving doxil, carboplatin, surgery or paclitaxel treatments that are still open to participants."
Is this a newly implemented trial?
"Since 1997, when the Alfacell Corporation initiated its first clinical trial involving 300 patients, Treatment (doxil, carboplatin, surgery and paclitaxel) has been subject to extensive research. It was officially given Phase 3 drug approval following that initial study. Presently there are 1,380 active trials examining this treatment in 86 nations across 3641 cities worldwide."
Are there still openings for prospective participants in this clinical trial?
"At this time, no further participants are being accepted for the trial. Initially posted on February 25th 2015 and lastly updated March 28th 2023, alternative trials with similar aims can be found; 2386 actively recruiting studies concerning breast cancer and 1380 investigating Treatment (doxil, carboplatin, surgery, paclitaxel) have openings."
What aims is this research endeavor hoping to achieve?
"This trial will be assessing pathologic complete response (pCR) rates as its chief outcome. Secondary objectives include analyzing mutational spectrum of tumors though Cox model analysis, monitoring recurrence-free survival with the Kaplan-Meier method, and utilizing quality of life surveys to assess patient wellbeing. All tests shall occur at a significance level of 5%. By evaluating these outcomes between mutation status groups over time intervals ranging from 28 days to 28 weeks post baseline evaluation it is hoped that this research can determine which tumours are most susceptible to targeted agents or combination therapies and also understand any additive/synergistic effects they may have on patients' health stat"
Share this study with friends
Copy Link
Messenger